☆ 4.1 Review

Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity

CURRENT OPINION IN CARDIOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial

Domenica M. Rubino et al.

Summary: In overweight or obese adults without diabetes, once-weekly subcutaneous semaglutide resulted in significantly greater weight loss compared to once-daily subcutaneous liraglutide when added to counseling for diet and physical activity over 68 weeks.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis

Ping Zhong et al.

Summary: This meta-analysis examined the effectiveness and safety of once-weekly semaglutide in treating overweight or obese adults. The results showed that once-weekly semaglutide was superior to placebo in terms of weight loss, achievement of weight reduction targets, cardiometabolic risk reduction, and improvement in health-related quality of life.

ENDOCRINE (2022)

Add to Collection

Review Endocrinology & Metabolism

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Donna H. Ryan

Summary: A new generation of antiobesity drugs, including setmelanotide and semaglutide, have been approved or are seeking approval, presenting new possibilities for obesity treatment. These developments have generated significant interest and hold promise for the future of obesity pharmacotherapy.

JOURNAL OF OBESITY & METABOLIC SYNDROME (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Disease and Stroke Statistics-2021 Update A Report From the American Heart Association

Salim S. Virani et al.

Summary: The American Heart Association, in partnership with the National Institutes of Health, publishes annual statistics on heart disease, stroke, and cardiovascular risk factors, including the impact of health behaviors and factors on cardiovascular health. The Statistical Update covers a range of clinical heart and circulatory conditions, providing data on quality of care, procedures, and economic costs. It serves as a critical resource for various stakeholders seeking the best available data on these factors and conditions.

CIRCULATION (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial

Thomas A. Wadden et al.

Summary: This study compared the effects of once-weekly subcutaneous semaglutide with placebo as an adjunct to intensive behavioral therapy and initial low-calorie diet for weight management in adults with overweight or obesity. The results showed that semaglutide led to significantly greater weight loss compared to placebo over 68 weeks, with a higher proportion of participants achieving weight loss goals. More research is needed to evaluate the long-term effectiveness of this treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies et al.

Summary: In this study, once-weekly subcutaneous semaglutide 2.4 mg was shown to achieve a significantly greater and clinically meaningful weight reduction compared to placebo in adults with overweight or obesity and type 2 diabetes. Adverse events, particularly gastrointestinal events, were more common with semaglutide compared to placebo.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Endocrinology & Metabolism

被撤回的出版物: The best drug supplement for obesity treatment: a systematic review and network meta-analysis (Retracted article. See vol. 15, 2023)

Nader Salari et al.

Summary: This study conducted a systematic review and network meta-analysis comparing different anti-obesity drugs, and found that phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide were the most effective drugs for weight loss compared to placebo treatment. This research provides new insights into anti-obesity drugs and may guide future research on managing and treating obesity.

DIABETOLOGY & METABOLIC SYNDROME (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial

Domenica Rubino et al.

Summary: Continuing treatment with semaglutide resulted in greater weight loss maintenance and improvement in other physical indicators compared to switching to placebo over a 48-week period in adults with overweight or obesity. The study also found that gastrointestinal events were more common with continued semaglutide, but discontinuation rates were similar between the two groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Julie R. Lundgren et al.

Summary: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. The combination strategy led to greater weight loss and improvements in metabolic health-related indicators.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder

Elvira Anna Carbone et al.

Summary: The study evaluates the efficacy of naltrexone and bupropion sustained release (NB) in improving pathological eating behavior and losing weight in obese patients with binge eating disorder (BED). It found that treatment with NB significantly reduced weight, improved pathological eating behavior, and was well tolerated, making it a suitable option for obese patients with BED.

EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY (2021)

Add to Collection

Article Medicine, General & Internal

Obesity in adults: a clinical practice guideline

Sean Wharton et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

Add to Collection

Article Endocrinology & Metabolism

The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity

Minyi Lee et al.

OBESITY SCIENCE & PRACTICE (2020)

Add to Collection

Review Endocrinology & Metabolism

Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes

Ronald M. Goldenberg et al.

CANADIAN JOURNAL OF DIABETES (2019)

Add to Collection

Article Medicine, General & Internal

Projected US State-Level Prevalence of Adult Obesity and Severe Obesity

Zachary J. Ward et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Endocrinology & Metabolism

Progress and challenges in anti-obesity pharmacotherapy

Daniel H. Bessesen et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Simulation of Growth Trajectories of Childhood Obesity into Adulthood

Zachary J. Ward et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Pharmacology & Pharmacy

Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk

Sarmad Said et al.

CURRENT VASCULAR PHARMACOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

W. Timothy Garvey et al.

ENDOCRINE PRACTICE (2016)

Add to Collection

Article Endocrinology & Metabolism

European Guidelines for Obesity Management in Adults

Volkan Yumuk et al.

OBESITY FACTS (2015)

Add to Collection

Article Medicine, General & Internal

Long-Term Persistence of Hormonal Adaptations to Weight Loss

Priya Sumithran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.